UiPath Vs. ServiceNow: Which Agentic AI Stock Is the Better Buy?

The key market mechanism is not “agentic AI winners” so much as who owns the workflow layer when AI agents move from demos to procurement. NOW has the better enterprise distribution and can use that to bundle higher-value modules, while PATH’s opportunity is more about operating leverage and surviving a category shift where standalone automation can be displaced by broader platforms from MSFT, CRM, and NOW itself. That creates a subtle loser/risk: if agents become a feature inside suite vendors, PATH’s margin expansion can happen alongside slower terminal growth, which is usually a poor setup for multiple expansion.

Time horizon matters. In the next 1-3 months, the stock reaction will likely be driven more by whether managements can show attach-rate, billings, and seat expansion than by the AI narrative itself. Over 6-18 months, the real question is whether PATH can sustain profitability without a deceleration in top-line quality; if not, the market will re-rate it as a low-growth software turn-around rather than an AI compounder. For NOW, the risk is that premium pricing already discounts continued enterprise outperformance; any net income disappointment can cap multiple expansion even if revenue stays healthy.

The consensus may be underestimating how quickly the market can start rewarding PATH for proving durable margins, but it may also be overestimating how much upside exists for NOW from an AI label that could simply accelerate existing workflow spend. The cleanest setup is relative value: PATH has more valuation torque if profitability holds, while NOW is the higher-quality compounder but less likely to surprise. Watch for gross margin, RPO/billings conversion, and any commentary that agentic features are sold as add-ons versus bundled into core suites; that will determine whether this is a two-stock story or a winner-take-more platform shift.